Bionpharma – Recall of clobazam oral suspension

- On July 31, 2019, the FDA enforcement report announced a class II, patient-level recall of one lot of Bionpharma's clobazam oral suspension due to microbial contamination.

Product Description	NDC#	Lot# (Expiration Date)
Clobazam oral suspension, 2.5 mg/mL, 120 mL bottle	69452-116-45	18246 (9/2020)

- Clobazam oral suspension is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 2 years of age or older.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the recalled clobazam oral suspension.
- Anyone with an existing inventory of the recalled product should stop use and distribution, and quarantine the product immediately.
- For more information regarding this recall, contact Bionpharma at **1-888-235-2466**.